iRhythm Technologies $IRTC Shares Bought by Values First Advisors Inc.

Values First Advisors Inc. raised its stake in iRhythm Technologies (NASDAQ:IRTC) by 5.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,525 shares of the company’s stock after acquiring an additional 322 shares during the quarter. Values First Advisors Inc.’s holdings in iRhythm Technologies were worth $1,005,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. MCF Advisors LLC acquired a new position in iRhythm Technologies in the first quarter valued at $25,000. AlphaQuest LLC acquired a new position in iRhythm Technologies in the first quarter valued at $30,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in iRhythm Technologies in the first quarter valued at $50,000. CWM LLC increased its stake in iRhythm Technologies by 54.3% in the first quarter. CWM LLC now owns 517 shares of the company’s stock valued at $54,000 after purchasing an additional 182 shares during the last quarter. Finally, US Bancorp DE increased its stake in iRhythm Technologies by 61.9% in the first quarter. US Bancorp DE now owns 978 shares of the company’s stock valued at $102,000 after purchasing an additional 374 shares during the last quarter.

Insider Activity

In other iRhythm Technologies news, CFO Daniel G. Wilson sold 5,000 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $175.00, for a total transaction of $875,000.00. Following the completion of the transaction, the chief financial officer directly owned 34,470 shares of the company’s stock, valued at approximately $6,032,250. This trade represents a 12.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Abhijit Y. Talwalkar sold 5,312 shares of the stock in a transaction on Monday, August 11th. The shares were sold at an average price of $158.02, for a total value of $839,402.24. Following the transaction, the director directly owned 20,299 shares of the company’s stock, valued at approximately $3,207,647.98. The trade was a 20.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,069 shares of company stock worth $7,627,986 in the last quarter. 1.10% of the stock is currently owned by corporate insiders.

iRhythm Technologies Stock Performance

Shares of IRTC stock opened at $181.02 on Friday. iRhythm Technologies has a 12-month low of $60.69 and a 12-month high of $187.57. The firm has a market capitalization of $5.82 billion, a price-to-earnings ratio of -61.78 and a beta of 1.15. The business has a 50 day simple moving average of $172.67 and a 200 day simple moving average of $146.21. The company has a debt-to-equity ratio of 6.25, a current ratio of 5.02 and a quick ratio of 4.88.

iRhythm Technologies (NASDAQ:IRTC) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.21. iRhythm Technologies had a negative return on equity of 90.03% and a negative net margin of 14.06%.The business had revenue of $186.69 million during the quarter, compared to analyst estimates of $173.94 million. During the same period in the prior year, the company posted ($0.61) EPS. The business’s revenue for the quarter was up 26.1% compared to the same quarter last year. iRhythm Technologies has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that iRhythm Technologies will post -1.98 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on IRTC shares. Weiss Ratings reissued a “sell (d-)” rating on shares of iRhythm Technologies in a research report on Wednesday, October 8th. BTIG Research upped their target price on iRhythm Technologies from $190.00 to $195.00 and gave the stock a “buy” rating in a research report on Monday. Wells Fargo & Company upped their target price on iRhythm Technologies from $130.00 to $180.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Morgan Stanley decreased their target price on iRhythm Technologies from $160.00 to $147.00 and set an “overweight” rating for the company in a research report on Tuesday, July 15th. Finally, William Blair raised iRhythm Technologies to a “strong-buy” rating in a research report on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $184.85.

iRhythm Technologies Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.